Issue of Equity
IXICO plc has confirmed that all conditions for its First Placing and Subscription have been met, having received Advance Assurance from HM Revenue & Customs. Following this, Directors Mark Warne, Bram Goorden, and Katherine Rogers subscribed for new ordinary shares, acquiring 125,000, 937,500, and 62,500 shares respectively, at a price of 8 pence per share. These subscriptions result in their new total holdings being 197,335, 1,463,815, and 115,131 ordinary shares. The company anticipates First Admission to AIM on 24 April 2026 and Second Admission on 27 April 2026, after which the total number of ordinary shares in issue will be 218,047,596.
Select text to share a quote on X · sign in to keep highlights & notes in your IXI notes
IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that further to the 'Placings and Subscription' announcement dated 31 March 2026, the Company is pleased to confirm that it has now received Advance Assurance from HM Revenue & Customs under the Income Tax Act 2007. Consequently, all conditions relating to the First Placing and Subscription have been satisfied.
Director Shareholdings
| Name | Number of existing Ordinary Shares | Number of Subscription Shares subscribed for (1) | Number of Ordinary Shares held following Admission |
|---|---|---|---|
| Mark Warne | 72,335 | 125,000 | 197,335 |
| Bram Goorden | 526,315 | 937,500 | 1,463,815 |
| Katherine Rogers | 52,631 | 62,500 | 115,131 |
Admission and Total Voting Rights
Application has been made for the New Ordinary Shares to be admitted to trading on AIM. It is expected that First Admission will become effective at 8.00 a.m. on 24 April 2026 and Second Admission will become effective at 8.00 a.m. on 27 April 2026.
Following First Admission and Second Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 218,047,596 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Fist Admission and Second Admission, the total number of voting rights in the Company will be 218,047,596.
Capitalised terms used in this announcement have the meaning given to them in the announcement dated 31 March 2026, unless otherwise defined in this announcement.
Giles Balleny, Isaac Hooper, Andrea Callaghan (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales)
| 2 | Reason for the notification | |||||
| a) | Position/status | 1. Chairman 2. Chief Executive Officer 3. Non-Executive Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| a) | Name | IXICO plc | ||||
| b) | LEI | 2138005M1F59O6HWSA97 | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each GB00BFXR4C20 | ||||
| b) | Nature of the transaction | 1, 2 & 3: Subscription for New Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
pence 125,000 2 8 pence 937,500 3 8 pence 62,500 | ||||
| d) | Aggregated information - Aggregated volume - Price | N/A - single transaction | ||||
| e) | Date of the transaction | 23 April 2026 | ||||
| f) | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.